CN111925360B - 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 - Google Patents

用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 Download PDF

Info

Publication number
CN111925360B
CN111925360B CN202010607608.6A CN202010607608A CN111925360B CN 111925360 B CN111925360 B CN 111925360B CN 202010607608 A CN202010607608 A CN 202010607608A CN 111925360 B CN111925360 B CN 111925360B
Authority
CN
China
Prior art keywords
compound
pyrrolidine
tert
mmol
butyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CN202010607608.6A
Other languages
English (en)
Chinese (zh)
Other versions
CN111925360A (zh
Inventor
谢玲红
菲利普·格林·琼斯
凯瑞·L·斯皮尔
诺尔·阿伦·鲍威尔
泰琳·G·阿纳尼亚
瓦迪姆·亚历山德罗夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pgi Drug Development Corp
Sumitomo Pharma America Inc
Original Assignee
Pgi Drug Development Corp
Sunovion Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pgi Drug Development Corp, Sunovion Pharmaceuticals Inc filed Critical Pgi Drug Development Corp
Priority to CN202010607608.6A priority Critical patent/CN111925360B/zh
Publication of CN111925360A publication Critical patent/CN111925360A/zh
Application granted granted Critical
Publication of CN111925360B publication Critical patent/CN111925360B/zh
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D493/00—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system
    • C07D493/02—Heterocyclic compounds containing oxygen atoms as the only ring hetero atoms in the condensed system in which the condensed system contains two hetero rings
    • C07D493/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202010607608.6A 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物 Expired - Fee Related CN111925360B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202010607608.6A CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562115064P 2015-02-11 2015-02-11
US62/115,064 2015-02-11
CN202010607608.6A CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物
PCT/US2016/017539 WO2016130796A1 (en) 2015-02-11 2016-02-11 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
CN201680018639.XA CN107531674B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201680018639.XA Division CN107531674B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Publications (2)

Publication Number Publication Date
CN111925360A CN111925360A (zh) 2020-11-13
CN111925360B true CN111925360B (zh) 2024-03-22

Family

ID=55456908

Family Applications (2)

Application Number Title Priority Date Filing Date
CN202010607608.6A Expired - Fee Related CN111925360B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物
CN201680018639.XA Expired - Fee Related CN107531674B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201680018639.XA Expired - Fee Related CN107531674B (zh) 2015-02-11 2016-02-11 用于治疗cns障碍的1-杂环基异苯并二氢吡喃基化合物和类似物

Country Status (22)

Country Link
US (4) US9856238B2 (enExample)
EP (2) EP4046995B1 (enExample)
JP (3) JP6657241B2 (enExample)
KR (1) KR102601972B1 (enExample)
CN (2) CN111925360B (enExample)
AU (1) AU2016219253C1 (enExample)
CA (1) CA2976095C (enExample)
CY (1) CY1125198T1 (enExample)
DK (1) DK3256466T3 (enExample)
EA (1) EA201791804A1 (enExample)
ES (2) ES2967643T3 (enExample)
HU (1) HUE058698T2 (enExample)
IL (1) IL253914B (enExample)
MX (2) MX392664B (enExample)
MY (1) MY188160A (enExample)
NZ (1) NZ735011A (enExample)
PH (1) PH12017501422A1 (enExample)
PL (1) PL3256466T3 (enExample)
PT (1) PT3256466T (enExample)
SG (2) SG10201806809QA (enExample)
UA (1) UA122222C2 (enExample)
WO (1) WO2016130796A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA122222C2 (uk) * 2015-02-11 2020-10-12 Суновіон Фармасьютикалз Інк. Сполуки 1-гетероцикліл-ізохроманілу і аналоги для лікування розладів цнс
US9758529B2 (en) * 2015-02-11 2017-09-12 Sunovion Pharmaceuticals Inc. Fused dihydro-4H-pyrazolo[5,1-C][1,4]oxazinyl compounds and analogs for treating CNS disorders
BR112019001407A2 (pt) 2016-07-29 2019-07-09 Sunovion Pharmaceuticals Inc. compostos e composições e usos dos mesmos
SG10202100724UA (en) 2016-07-29 2021-03-30 Sunovion Pharmaceuticals Inc Compounds and compositions and uses thereof
AU2018258117A1 (en) 2017-04-24 2019-12-12 Chase Therapeutics Corporation Compositions and method for treating depression
AU2018290889B2 (en) 2017-06-30 2024-06-27 Alto Neuroscience, Inc. NK-1 antagonist compositions and methods for use in treating depression
MX2020000523A (es) 2017-08-02 2020-08-20 Sunovion Pharmaceuticals Inc Compuestos de isocromano y usos de los mismos.
US20210393621A1 (en) 2018-10-26 2021-12-23 The Research Foundation For The State University Of New York Combination serotonin specific reuptake inhibitor and serotonin 1a receptor partial agonist for reducing l-dopa-induced dyskinesia
JP7703449B2 (ja) 2019-03-14 2025-07-07 スミトモ・ファーマ・アメリカ・インコーポレイテッド イソクロマニル化合物の塩およびその結晶体、ならびにそれらの製造方法、治療用途および医薬組成物
US12077546B2 (en) 2021-04-10 2024-09-03 Sumitomo Pharma Co., Ltd. Bicyclic pyridine derivative

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238939A (en) * 1990-05-25 1993-08-24 Akzo N.V. Isochromane derivatives
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3438995A (en) 1968-01-08 1969-04-15 Melville Sahyun Diazaheterocyclic substituted benz-oxaheterocyclic compounds
US4963568A (en) 1989-05-31 1990-10-16 Abbott Laboratories Dopamine agonists
US5621133A (en) 1989-05-31 1997-04-15 Deninno; Michael P. Dopamine agonists
IE73232B1 (en) * 1990-05-25 1997-05-21 Akzo Nv Isochromane derivatives
EP1089993B1 (en) 1998-06-30 2003-10-22 Eli Lilly And Company 5-ht1f agonists
SE9902267D0 (sv) * 1999-06-16 1999-06-16 Astra Ab New compounds
CA2465186A1 (en) * 2001-11-08 2003-05-15 Sepracor, Inc. Methods for treating depression and other cns disorders using enantiomerically enriched desmethyl- and didesmethyl-metabolites of citalopram
WO2006066756A1 (en) * 2004-12-21 2006-06-29 F. Hoffmann-La Roche Ag Chroman derivatives and uses thereof in the treatment of cns disorders
JP2008538576A (ja) 2005-04-22 2008-10-30 ワイス クロマンおよびクロメン誘導体およびその使用
KR20080090545A (ko) * 2006-01-27 2008-10-08 에프. 호프만-라 로슈 아게 Cns 장애 치료용 2-이미다졸의 용도
KR101103118B1 (ko) 2007-11-02 2012-01-04 동아제약주식회사 신규한 1,3-디히드로-5-이소벤조퓨란카르보니트릴 유도체 화합물 및 이를 함유하는 조루증 치료용 약학조성물
CN104193761B (zh) * 2009-12-04 2017-10-17 桑诺维恩药品公司 多环化合物及其使用方法
US8569339B2 (en) 2011-03-10 2013-10-29 Boehringer Ingelheim International Gmbh Soluble guanylate cyclase activators
AR090557A1 (es) * 2012-04-02 2014-11-19 Orion Corp DERIVADOS IMIDAZOLICOS AGONISTAS ADRENERGICOS a2
UA122222C2 (uk) * 2015-02-11 2020-10-12 Суновіон Фармасьютикалз Інк. Сполуки 1-гетероцикліл-ізохроманілу і аналоги для лікування розладів цнс

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5238939A (en) * 1990-05-25 1993-08-24 Akzo N.V. Isochromane derivatives
WO2014106238A1 (en) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Heterocyclic compounds and methods of use thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Martial Toffano,et al..Asymmetric routes towards polyfunctionalized pyrrolidines: application to the synthesis of alkaloid analogues.《Tetrahedron: Asymmetry》.2003,第14卷3365-3370. *

Also Published As

Publication number Publication date
CN111925360A (zh) 2020-11-13
US11192885B2 (en) 2021-12-07
US20180093974A1 (en) 2018-04-05
KR20170129730A (ko) 2017-11-27
MX392664B (es) 2025-03-24
PH12017501422A1 (en) 2018-03-19
DK3256466T3 (da) 2022-05-02
PT3256466T (pt) 2022-05-10
AU2016219253C1 (en) 2022-12-08
US20170001987A1 (en) 2017-01-05
JP2018505205A (ja) 2018-02-22
AU2016219253A1 (en) 2017-09-21
ES2967643T3 (es) 2024-05-03
KR102601972B1 (ko) 2023-11-13
WO2016130796A1 (en) 2016-08-18
HUE058698T2 (hu) 2022-09-28
EP4046995C0 (en) 2023-09-13
UA122222C2 (uk) 2020-10-12
ES2911910T3 (es) 2022-05-23
MX371404B (es) 2020-01-29
EP3256466B9 (en) 2022-07-27
BR112017017354A2 (pt) 2018-04-10
JP2020079282A (ja) 2020-05-28
SG11201706515QA (en) 2017-09-28
EP3256466A1 (en) 2017-12-20
CY1125198T1 (el) 2024-12-13
CN107531674A (zh) 2018-01-02
JP6657241B2 (ja) 2020-03-04
EP3256466B1 (en) 2022-04-06
CA2976095A1 (en) 2016-08-18
MY188160A (en) 2021-11-24
MX2017010363A (es) 2018-05-04
SG10201806809QA (en) 2018-09-27
IL253914B (en) 2021-09-30
US9856238B2 (en) 2018-01-02
CN107531674B (zh) 2020-07-31
EP4046995B1 (en) 2023-09-13
EA201791804A1 (ru) 2018-02-28
ES2911910T9 (es) 2022-08-12
NZ735011A (en) 2023-07-28
US20220185799A1 (en) 2022-06-16
JP2022065050A (ja) 2022-04-26
US20190389845A1 (en) 2019-12-26
JP7023994B2 (ja) 2022-02-22
CA2976095C (en) 2023-10-17
PL3256466T3 (pl) 2022-05-23
AU2016219253B2 (en) 2020-10-01
US10336732B2 (en) 2019-07-02
IL253914A0 (en) 2017-10-31
EP4046995A1 (en) 2022-08-24
MX2020001157A (es) 2022-05-27

Similar Documents

Publication Publication Date Title
JP7023994B2 (ja) Cns疾患を治療するための1-複素環イソクロマニル化合物およびアナログ
JP2023036611A (ja) Cns疾患を治療するための縮合ジヒドロ-4h-ピラゾロ[5,1-c][1,4]オキサジニル化合物およびアナログ
US11491133B2 (en) Heteroaryl-isochroman compounds and uses thereof
HK40042391A (en) 1-heterocyclyl isochromanyl compounds and analogus for treating cns disorders
HK40078692B (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK40078692A (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK1241876A1 (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
HK1241876B (en) 1-heterocyclyl isochromanyl compounds and analogs for treating cns disorders
EA046724B1 (ru) Соединения 1-гетероциклил изохроманила и аналоги для лечения расстройств цнс
BR112017017354B1 (pt) Composto e seu uso, composição, processo para preparar um composto
HK40025044B (en) Isochroman compounds and uses thereof
HK40025044A (en) Isochroman compounds and uses thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40042391

Country of ref document: HK

GR01 Patent grant
GR01 Patent grant
CF01 Termination of patent right due to non-payment of annual fee

Granted publication date: 20240322

CF01 Termination of patent right due to non-payment of annual fee